产品
编 号：F199016
分子式：C14H12ClN3O4S2
分子量：385.85
分子式：C14H12ClN3O4S2
分子量：385.85
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 165668-41-7
产品详情
生物活性：
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
体内研究：
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models.Animal Model:Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models).
Dosage:12.5, 25, 50 (100) mg/kg.
Administration:IV daily for 4 days.
Result:Exhibited anti-tumor activity.
体外研究：
Indisulam (E7070, 0-50 μg/mL, 12-48 h) causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death.
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
体内研究：
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models.Animal Model:Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models).
Dosage:12.5, 25, 50 (100) mg/kg.
Administration:IV daily for 4 days.
Result:Exhibited anti-tumor activity.
体外研究：
Indisulam (E7070, 0-50 μg/mL, 12-48 h) causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备